找回密码
 立即注册

微信扫码登录

搜索

[围术期有驱动] NAUTIKA1:迪法雷塞(Divarasib)新辅助治疗可切除KRAS G12C突变非小细胞肺癌

[复制链接]
阳光肺科 发表于 2026-10-29 14:50:24 | 显示全部楼层 |阅读模式
Neoadjuvant Divarasib Shows Manageable Safety and Promising Activity in Resectable KRAS G12C+ NSCLC: Updated NAUTIKA1 Data
Neoadjuvant Divarasib Shows Manageable Safety and Promising Activity in Resectable KRAS G12C+ NSCLC: Updated NAUTIKA1 Data
Jamie E. Chaft,1 Amy Cummings,2 Nisha Mohindra,3 Marcelo V. Negrao,4 Kai He,5 So Yeon Kim,6 Andreas Saltos,7 Tejas Patil,8 Elaine Shum,9 Philip Lammers,10 Katja Schulze,11 Qian Zhu,11 Mark T. Lin,11 Evelise Brandao,11 Celina Ngiam,11 Ilze Bara,11 Jay M. Lee2


KRAS G12C mutations are present in 12–14% of NSCLC cases and associated with poor prognosis1
Divarasib, a next-generation KRAS G12C inhibitor, showed a durable clinical benefit and manageable safety profile in patients with previously treated, advanced or metastatic KRAS G12C+ NSCLC2–4
In the phase III, Krascendo 1 study (NCT06497556) divarasib significantly improved PFS and OS compared with the approved KRAS G12C inhibitors sotorasib and adagrasib4
NAUTIKA1 (NCT04302025) is a phase II, umbrella study evaluating multiple neoadjuvant and adjuvant treatments for early-stage NSCLC with specific oncogenic drivers, including: KRAS G12C, ALK, ROS1, snd NTRK, as well as a PD-L1 selected cohort5

NAUTIKA1:Ⅱ-Ⅲ期驱动基因阳性可切除NSCLC的新辅助和辅助治疗伞式试验




给我们建议|手机版|阳光肺科 ( 粤ICP备2020077405号-1 )

GMT+8, 2026-11-23 00:14

Powered by Discuz! X3.5

© 2001-2026 Discuz! Team.

快速回复 返回顶部 返回列表